NCT01828476View on ClinicalTrials.gov

Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

February 29, 2016

Study Completion Date

March 3, 2016

Conditions
Prostate Cancer
Interventions
DRUG

Abiraterone

ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)

DRUG

ABT-263

ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)

DRUG

Hydroxychloroquine

ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)

Trial Locations (1)

08901

Rutgers Cancer Institute of New Jersey, New Brunswick

Sponsors

Collaborators (1)

AbbVie
All Listed Sponsors
collaborator

Rutgers Cancer Institute of New Jersey

OTHER

collaborator

National Cancer Institute (NCI)

NIH

collaborator

AbbVie

INDUSTRY

lead

Rutgers, The State University of New Jersey

OTHER